Summary: Diabetic kidney disease is a significant public health problem, being the most frequent cause of end-stage kidney disease in developed countries. Therefore there is an urgent need for therapies that slow renal disease progression and improve outcomes. Sodium-glucose co-transporter2 (SGLT2) inhibitors, also called gliflozins, are a new group of oral hypoglycemic agents used to treat type 2 diabetes, diminishing renal tubular glucose reabsorption, with a reduction in blood glucose without stimulating insulin release. However, it has become apparent that they also have significant cardiovascular and renal benefits that seem more valuable than their modest effect on glycemic control. This paper summarizes the results of five recent international multicenter randomized studies performed in patients with type 2 diabetes with a high risk of cardiovascular and renal outcomes, which can reshape the management of this population.